Ascentage Pharma Group International (AAPG) Total Current Liabilities (2023 - 2025)

Ascentage Pharma Group International (AAPG) has reported Total Current Liabilities for 3 consecutive years, with $231.7 million the latest figure, recorded in Q4 2025.

• Quarterly Total Current Liabilities rose 42.67% year-over-year to $231.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $231.7 million (up 42.67% YoY) and the FY2025 annual result came in at $235.0 million, up 47.04% from the prior year.
• Total Current Liabilities fell to $231.7 million in Q4 2025 per AAPG's latest filing, from $252.2 million in the prior quarter.
• Over the last five years, Total Current Liabilities for AAPG reached as high as $252.2 million in Q2 2025 and fell as low as $129.7 million in Q4 2023.
• A 3-year average of $194.0 million and a median of $197.1 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities gained 25.18% — and 2025, when it surged 42.67%.
• Year by year, Total Current Liabilities stood at $129.7 million in 2023, then rose by 25.18% to $162.4 million in 2024, then jumped by 42.67% to $231.7 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $231.7 million, $252.2 million, and $162.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.